ClinicalTrials.gg
CompletedNCT03945318Updated Jun 16, 2026

Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)

A Phase 1/2 interventional study of BION-1301 Single Dose and Placebo Single Dose in IgA Nephropathy, sponsored by Novartis Pharmaceuticals. Completed at 16 sites in 3 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-16.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
103
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Glomerulonephritis, IGA by Novartis — 9 open to participants now, 12 under way, 7 of them phase 3. Glomerulonephritis, IGA · Novartis.

Enrollment
8th of 14
103 · median 108
Started
2019
the only one that year
Phase 1/2
Only one
of the 18
Registered
2nd of 18
by date

Among the 18 studies in Glomerulonephritis, IGA by Novartis, this one is the 8th largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2019, is the only one in phase 1/2, and was the 2nd registered.

Glomerulonephritis, IGA

276 studies on the registry are indexed under Glomerulonephritis, IGA; 108 are open to participants now.

Browse Glomerulonephritis, IGA studies →

Open to participants now

9 of the 18 studies in Glomerulonephritis, IGA by Novartis are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 68 Glomerulonephritis, IGA studies recruiting now, 39 (57%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Glomerulonephritis, IGA by Novartis, or all of them as a file.
02

Study summary

Multicenter study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of BION-1301 in healthy volunteers and adults with IgA Nephropathy (IgAN).

Read the detailed description

This is a Phase 1/2 study of BION-1301, a first-in-class humanized IgG4 anti-a proliferation-inducing ligand (APRIL) monoclonal antibody.

The study was conducted in four parts. Part 1: double-blind, randomized, placebo-controlled, single ascending dose (SAD) in healthy volunteers (HVs). Part 2: double-blind, randomized, placebo-controlled multiple ascending dose (MAD) in HVs. Part 3: Open-label, multiple dose (MD) in participants with IgAN. Part 4: Retreatment period

The study planned to enroll up to 40 participants with IgAN.

03

Conditions studied

  • IgA Nephropathy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria for Healthy Volunteers:

  1. Healthy male or female volunteers, 18 to 55 years old
  2. Females must be of non-
  3. Males must agree to follow the protocol-specified guidance
  4. (BMI) between 18 and 35 kg/m\^2, with a weight of at least 50 kg
  5. Non-smoker, defined as an individual who has not smoked previously and/or who has discontinued smoking or the use of nicotine/nicotine-containing products at least 3 months before Screening
  6. Able to provide signed

Exclusion Criteria for Healthy Volunteers:

  1. Regular consumption of alcohol within 6 months prior to Screening, or use of soft drugs (such as marijuana) within 3 months prior to Screening, or hard drugs (such as cocaine and phencyclidine) within 1 year prior to Screening and/or positive blood or urine test results for drugs of abuse or alcohol at Screening or Admission
  2. Donated blood in the 3 months prior to the first dose of study drug, plasma in the 7 days prior to the first dose of study drug, or in the 6 weeks prior to the first dose of study drug
  3. History or evidence of a disorder, condition, or disease that could pose a risk to participant safety or interfere with the study, or would make the participant unsuitable for participation, eg, respiratory, renal, hepatic, gastrointestinal, hematological, lymphatic, neurological, cardiovascular, or psychiatric disease
  4. Female who is breastfeeding or who has a positive serum pregnancy test at Screening or a positive urine pregnancy test on Day -1

Inclusion Criteria for Adults with IgAN:

  1. Male or female ≥18 years old at Screening
  2. Women of child-bearing potential (WOCBP; per CTFG 2014) must agree to follow the protocol-specified contraception guidance throughout the study (from Screening through approximately 6 months after the final dose of study drug)
  3. Males must agree to follow the protocol-specified contraception guidance throughout the study (from Screening through approximately 6 months after the final dose of study drug)
  4. BMI between 18 and 40 kg/m\^2, inclusive, at Screening with a weight of at least 50 kg
  5. Diagnosis of IgAN verified by taken within the past 10 years
  6. Urine protein ≥ 0.5 g/24h; OR UPCR ≥ 0.5 g/g (or ≥ 50 mg/mmol)
  7. (per Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] formula) or measured GFR ≥ 30 mL/min per 1.73 m\^2
  8. Stable on an optimized dose of angiotensin converting enzyme (ACE) inhibitors and/or angiotensin-receptor blockers (ARBs) for at least 3 months prior to Screening or intolerant to ACE/ARB

Exclusion Criteria for Participant with IgAN:

  1. Known or suspected allergy or to any component of BION-1301, or history of severe hypersensitivity reaction to any monoclonal antibody
  2. Donated blood in the 3 months prior to the first dose of study drug; plasma in the 7 days prior to the first dose of study drug; or platelets in the 6 weeks prior to the first dose of study drug
  3. Participated in any other study in which receipt of an new drug, or investigational device occurred within 28 days, or 5 half-lives (whichever is longer) of first dose of study drug in the present study
  4. Secondary forms of IgAN as defined by the treating physician (eg, IgA vasculitis and those with associated alcoholic cirrhosis)
  5. Received systemic therapy (> 10 mg/day of prednisone or equivalent) or any other form of therapy within 3 months prior to the first dose of study drug

PART 4 Eligibility Criteria for Re-treatment Due to Evidence of Disease Progression

(Option 1) Inclusion Criteria for Re-treatment Due to Evidence of Disease Progression

  1. Completed Part 3 of the study through Week 124 and entered the 52-week follow-up period.
  2. UPCR ≥ 0.5 g/g AND ≥ 30% increase from EOT (Week 124). Both proteinuria criteria must be met by a 24-hour urine assessment during the 52-week follow-up period. In addition to the scheduled assessments, investigators may order periodic FMV assessments (for example monthly) to follow a participant more closely. Based on an off-schedule FMV result, or other laboratory or clinical evidence, investigators may order an off-schedule 24-urine collection to confirm disease progression.

Exclusion Criteria for Re-treatment Due to Evidence of Disease Progression

  1. Based on the Investigator's judgment, the participant would not benefit from resuming treatment with BION-1301 or there is a safety concern for the individual participant which outweighs the expected benefit from resuming treatment.
  2. Received systemic corticosteroid therapy, including budesonide, for >14 days within 3 months prior to the first dose of Part 4 for the treatment of IgAN
  3. Received any other form of immunosuppressive therapy such as, but not limited to mycophenolate mofetil, azathioprine, cyclosporine, tacrolimus, rituximab, cyclophosphamide, etc) within 3 months prior to the first dose of Part 4 study drug
  4. Received investigational products for the treatment of IgAN, other than BIO-1301
  5. Received newly approved immunosuppressive or immunomodulatory therapy for the treatment of IgAN including but not limited to other anti-APRIL therapies and iptacopan

Eligibility Criteria for Optional Re-treatment (Option 2)

Inclusion Criteria for Optional Re-treatment

1. Completed Part 3 of the study through Week 124 and completed of the 52-week follow-up period.

Exclusion Criteria for Optional Re-treatment

  1. Based on the Investigator's judgment, the participant would not benefit from resuming treatment with BION-1301 or there is a safety concern for the individual participant which outweighs the expected benefit from resuming treatment.
  2. Received systemic corticosteroid therapy, including budesonide, for >14 days within 3 months prior to the first dose in Part 4 for the treatment of IgAN
  3. Received any other form of immunosuppressive therapy (such as, but not limited to mycophenolate mofetil, azathioprine, cyclosporine, tacrolimus, rituximab, cyclophosphamide, etc) within 3 months prior to the first dose of Part 4 study drug
  4. Received investigational products for the treatment of IgAN, other than BIO-1301
  5. Received newly approved immunosuppressive or immunomodulatory therapy for the treatment of IgAN including but not limited to other anti-APRIL therapies and iptacopan
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
103 participants (actual)

Study arms

  • Experimental
    Part 1: BION-1301

    Up to 5 cohorts with single ascending doses of BION-1301 administered by intravenous (IV) infusion in healthy volunteers.

    Drug: BION-1301 Single Dose

  • Placebo comparator
    Part 1: Placebo

    Healthy Volunteers receive a single dose of placebo administered by IV infusion.

    Drug: Placebo Single Dose

  • Experimental
    Part 2: BION-1301

    Up to 4 cohorts with multiple doses of BION-1301 administered by intravenous (IV) infusion in healthy volunteers.

    Drug: BION-1301 Multiple Doses

  • Placebo comparator
    Part 2: Placebo

    Healthy Volunteers receive placebo by IV infusion.

    Drug: Placebo Multiple Doses

  • Experimental
    Part 3: BION-1301

    Two cohorts of participants with IgAN receive multiple doses of BION-1301 by IV infusion (Cohort 1) or SC injection (Cohort 2) at 600mg/biweekly.

    Drug: BION-1301 Multiple Doses

  • Experimental
    Part 4 Retreatment: BION-1301

    Eligible participants with IgAN from Part 3 may enroll in Part 4 due to disease progression or by choice for optional retreatment and receive SC injection at 600mg/biweekly.

    Drug: BION-1301 Single Dose

Interventions

  • A single IV infusion infusion of BION-1301 at doses ranging from 10 to 1350 mg, administered once

    Also known as: Zigakibart, FUB523

  • DrugPlacebo Single Dose

    A single IV infusion of placebo

  • Part 2: Multiple IV infusions of BION 1301 administered every 2 weeks (Q2W) at doses of 50 mg, 150 mg or 450 mg for up to 3 doses. Part 3: Repeated dosing of BION 1301: 450 mg IV Q2W for ≥24 weeks followed by 600 mg SC Q2W, or 600 mg SC Q2W throughout.

    Also known as: Zigakibart, FUB523

  • DrugPlacebo Multiple Doses

    Multiple IV infusions of placebo administered every 2 weeks for up to 3 doses

  • 600 mg SC injection every 2 weeks (Q2W) for retreatment, administered via vials or pre-filled syringes (PFS)

    Also known as: Zigakibart, FUB523

06

What researchers measure

Primary outcomes

  1. Number of participants with Treatment Emergent Adverse Events (TEAEs) and treatment-emergent serious adverse events (SAEs)

    TEAEs and SAEs are assessed throughout each participant's study participation according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE).

    Time frame: Up to 276 weeks

  2. Change from baseline in systolic and diastolic blood pressure

    Change from baseline in systolic and diastolic blood pressure

    Time frame: Baseline and up to 276 weeks.

  3. Change from baseline in estimated glomerular filtration rate (eGFR)

    Change from baseline in estimated glomerular filtration rate (eGFR)

    Time frame: Baseline and up to 276 weeks

Secondary outcomes

  1. Cmax

    Maximum observed concentration

    Time frame: Up to Day 85

  2. Tmax

    Time corresponding to occurrence of Cmax

    Time frame: Up to Day 85

  3. T½

    Apparent terminal elimination half life

    Time frame: Up to Day 85

  4. AUC

    Area under the concentration-time curve (AUC)

    Time frame: Up to Day 85

  5. Incidence of ADA and neutralizing antibodies (Nabs)

    Incidence of anti-drug antibodies (ADA) and neutralizing antibodies (Nabs)

    Time frame: Up to 276 weeks

  6. Change from baseline in immunoglobulin levels

    Change from baseline in immunoglobulin levels (IgA, IgG, IgM)

    Time frame: Baseline and up to 276 weeks

  7. Change from baseline in UPCR

    Change from baseline in urinary protein/creatinine ratio (UPCR) based on 24-hour urine collection

    Time frame: Up to 276 weeks

  8. Change from baseline in urinary protein excretion

    Change from baseline in urinary protein excretion based on 24-hour urine collection

    Time frame: Up to 276 weeks

07

Study locations

16 sites
  • Amicis Research Center
    Northridge, California 91324, United States
  • Colorado Kidney Care, P.C.
    Denver, Colorado 80230, United States
  • Nephrology Associates of Central Florida
    Orlando, Florida 32806, United States
  • Elixia Tampa, LLC
    Tampa, Florida 33618, United States
  • New York Nephrology
    Clifton Park, New York 12065, United States
  • Chris Sholer, P.C.
    Oklahoma City, Oklahoma 73116, United States
  • Liberty Research Center
    Arlington, Texas 76012, United States
  • Liberty Research Center
    Dallas, Texas 75230, United States
  • Prolato Clinical Research Center
    Houston, Texas 77054, United States
  • Soon Chun Hyang University Hospital Cheonan
    Cheonan, Chungcheongnam-do 31151, South Korea
  • Hallym University Sacred Heart Hospital
    Anyang-si, Gyeonggi-do 14068, South Korea
  • National Health Insurance Service Ilsan Hospital
    Goyang-si, Gyeonggi-do 10444, South Korea
  • Hanyang University Guri Hostpital
    Guri-si, Gyeonggi-do 11923, South Korea
  • Seoul National University Bundang Hospital
    Seongnam-si, Gyeonggi-do 13620, South Korea
  • Liverpool University Hospital NHS Foundation Trust
    Liverpool, England L7 8XP, United Kingdom
  • PAREXEL Early Phase Clinical Unit
    London, HA1 3UJ, United Kingdom
08

References and documents

Publications

  • Kooienga L, Lo J, Lee EY, Kim SG, Thomas H, Workeneh B, Agha I, Song Y, Smith W, van Eenennaam H, Van Elsas A, Dulos J, Barratt J. Zigakibart demonstrates clinical safety and efficacy in a Phase 1/2 trial of healthy volunteers and patients with IgA nephropathy. Kidney Int. 2025 Sep;108(3):445-454. doi: 10.1016/j.kint.2025.05.006. Epub 2025 Jun 5. PubMed 40482854 ↗

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data is currently available according to the process described on www.clinicalstudydatarequest.com.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2019 to primary completion in Jun 2026, 86 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2019
First posted
May 10, 2019
StartActual
Apr 8, 2019
Primary completionActual
Jun 10, 2026
CompletionActual
Jun 10, 2026
Last update
Jun 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03945318
Responsible party
Sponsor
First posted
May 10, 2019
Start date
Apr 8, 2019
Primary completion
Jun 10, 2026
Completion
Jun 10, 2026
Last update
Jun 16, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zigakibart

Start the discussion